IMM.AX Immutep Limited ASX down 88.61% on 13 Mar 2026: market closed, active traders watch

At market close on 13 Mar 2026 Immutep Limited (IMM.AX) traded at A$0.045 after an -88.61% one-day move on heavy volume of 432,932,084 shares. IMM.AX stock led ASX activity as the market reacted to the discontinuation of its lead clinical program and a wave of analyst downgrades. Traders saw the share price fall from a previous close of A$0.395, while the healthcare sector showed muted performance this session. We review the drivers, valuation, technicals and what active traders should watch next.

IMM.AX stock: price action and trading metrics

Immutep Limited (IMM.AX) closed at A$0.045 on 13 Mar 2026 after a session low of A$0.028 and high of A$0.050. Volume spiked to 432,932,084 shares versus an average volume of 3,122,827, making IMM.AX one of the most active ASX names. The company’s market capitalisation stands near A$581,408,534 and shares outstanding are 1,471,920,338.

IMM.AX stock news and catalyst summary

The immediate catalyst was the discontinuation of Immutep’s lead clinical program and subsequent analyst downgrades reported on 13 Mar 2026. Coverage includes reporting by Bloomberg and analyst notes on Investing.com that flagged rating cuts and client exposure. Read the original reporting on Bloomberg and the analyst coverage at Investing.com.

IMM.AX stock: fundamentals and valuation metrics

On trailing metrics Immutep shows an EPS of -0.06 and a negative P/E around -6.58, reflecting ongoing losses. Price-to-sales is elevated at 97.28 and price-to-book is 5.87, while the current ratio is 2.97, indicating short-term liquidity. Research and development spend is high, at roughly 6.04x revenue, which is typical for clinical-stage biotech but increases runway risk.

IMM.AX stock technicals and short-term trading setup

Momentum indicators show mixed readings: RSI near 52.31 and ADX 13.40 (no trend). Bollinger bands sit around middle A$0.38, but those reflect pre-drop levels given the extreme price gap. Active traders should watch intraday support at A$0.028 and any rebound above A$0.10 for short-covering signals, while volatility and order-book depth remain elevated.

Meyka AI grade and IMM.AX stock forecast

Meyka AI rates IMM.AX with a score out of 100: 62.29 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price near A$0.35 versus the current A$0.045, implying model-based upside of 684.78%; forecasts are model-based projections and not guarantees.

IMM.AX stock risks, sector context and opportunities

Primary risks are trial program setbacks, regulatory outcomes, and cash runway pressure after the discontinuation announcement. The healthcare sector on the ASX has been modest year-to-date, and Immutep’s biotech peers show higher median valuations. Opportunities include partnering deals or data readouts that could re-rate the stock, but these remain binary and high risk.

Final Thoughts

IMM.AX stock posted an extreme move at market close on 13 Mar 2026, trading A$0.045 on volume above 432.93M shares after the lead program halt and negative analyst reaction. The key takeaway for active traders is that the price drop creates both heavy short-covering potential and structural downside if no positive clinical update or corporate action emerges. Meyka AI’s forecast model projects a yearly value of A$0.35, implying +684.78% from the current price; this projection is model-based and not a guarantee. For risk-managed traders, a clear plan should define entry size, stop-loss levels, and timelines tied to corporate milestones. We note the current consensus rating environment and elevated valuation multiples; anyone trading IMM.AX must accept high volatility and binary outcomes. Meyka AI-powered market analysis platform flags this as a high-risk, high-volatility name for speculative positions.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.